Send to

Choose Destination
Crohns Colitis 360. 2019 Oct;1(3):otz026. doi: 10.1093/crocol/otz026. Epub 2019 Aug 19.

Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab.

Author information

Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.



We hypothesized that elevations of plasma Oncostatin M (OSM) would be associated with infliximab nonresponse.


Plasma OSM was measured in Crohn disease patients pre-infliximab with biochemical response (>50% reduction in fecal calprotectin) as the primary outcome.


The median OSM in biochemical responders was 86 (69-148) pg/mL compared with 166 (74-1766) pg/mL in nonresponders (P = 0.03). Plasma OSM > 143.5 pg/mL was 71% sensitive and 78% specific for biochemical nonresponse (area under the curve 0.71). Early biochemical nonremission was also associated with an elevated neutrophil CD64 expression (odds ratio 8.9, P = 0.011).


Elevated preinfliximab plasma OSM and nCD64 surface expression were both associated with poor biochemical outcomes.


Crohn disease; biomarkers; companion diagnostic; neutrophil CD64; pediatric

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center